1. Home
  2. SCYX vs GAME Comparison

SCYX vs GAME Comparison

Compare SCYX & GAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • GAME
  • Stock Information
  • Founded
  • SCYX 1999
  • GAME 2011
  • Country
  • SCYX United States
  • GAME United States
  • Employees
  • SCYX N/A
  • GAME N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • GAME
  • Sector
  • SCYX Health Care
  • GAME
  • Exchange
  • SCYX Nasdaq
  • GAME Nasdaq
  • Market Cap
  • SCYX 28.5M
  • GAME 27.2M
  • IPO Year
  • SCYX 2014
  • GAME 2009
  • Fundamental
  • Price
  • SCYX $0.71
  • GAME $2.20
  • Analyst Decision
  • SCYX
  • GAME Strong Buy
  • Analyst Count
  • SCYX 0
  • GAME 3
  • Target Price
  • SCYX N/A
  • GAME $3.67
  • AVG Volume (30 Days)
  • SCYX 115.9K
  • GAME 1.4M
  • Earning Date
  • SCYX 08-07-2025
  • GAME 08-13-2025
  • Dividend Yield
  • SCYX N/A
  • GAME N/A
  • EPS Growth
  • SCYX N/A
  • GAME N/A
  • EPS
  • SCYX N/A
  • GAME N/A
  • Revenue
  • SCYX $2,630,000.00
  • GAME $99,579,536.00
  • Revenue This Year
  • SCYX $463.61
  • GAME $6.08
  • Revenue Next Year
  • SCYX $310.80
  • GAME $21.94
  • P/E Ratio
  • SCYX N/A
  • GAME N/A
  • Revenue Growth
  • SCYX N/A
  • GAME 77.06
  • 52 Week Low
  • SCYX $0.66
  • GAME $0.50
  • 52 Week High
  • SCYX $2.29
  • GAME $1.64
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 40.46
  • GAME 92.95
  • Support Level
  • SCYX $0.70
  • GAME $0.73
  • Resistance Level
  • SCYX $0.75
  • GAME $0.97
  • Average True Range (ATR)
  • SCYX 0.04
  • GAME 0.18
  • MACD
  • SCYX 0.00
  • GAME 0.16
  • Stochastic Oscillator
  • SCYX 32.29
  • GAME 99.53

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About GAME GameSquare Holdings Inc.

GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.

Share on Social Networks: